Version 1
: Received: 21 November 2019 / Approved: 24 November 2019 / Online: 24 November 2019 (04:18:53 CET)
Version 2
: Received: 24 November 2019 / Approved: 24 November 2019 / Online: 24 November 2019 (16:29:54 CET)
How to cite:
Tang, X.; Zhang, C.; Chen, M.; Xue, Y.; Liu, T.; Xue, W. Synthesis and Antiviral Activity of Novel Myricetin Derivatives Containing a Ferulic Acid Amide Scaffolds. Preprints2019, 2019110263
Tang, X.; Zhang, C.; Chen, M.; Xue, Y.; Liu, T.; Xue, W. Synthesis and Antiviral Activity of Novel Myricetin Derivatives Containing a Ferulic Acid Amide Scaffolds. Preprints 2019, 2019110263
Cite as:
Tang, X.; Zhang, C.; Chen, M.; Xue, Y.; Liu, T.; Xue, W. Synthesis and Antiviral Activity of Novel Myricetin Derivatives Containing a Ferulic Acid Amide Scaffolds. Preprints2019, 2019110263
Tang, X.; Zhang, C.; Chen, M.; Xue, Y.; Liu, T.; Xue, W. Synthesis and Antiviral Activity of Novel Myricetin Derivatives Containing a Ferulic Acid Amide Scaffolds. Preprints 2019, 2019110263
Abstract
A variety of myricetin derivatives bearing ferulic acid amide scaffolds were designed and synthesized. The structures of all title compounds were determined by 1 H NMR, 13 C NMR, 19 F NMR and HRMS. Preliminary bioassays suggested that some of the target compounds exhibited remarkable antiviral activities. In particular, compound 4l possessed significant protection activity against tobacco mosaic virus (TMV), with an half maximal effective concentration (EC50) value of 196.11 μg/mL, which was better than commercial agent ningnamycin (447.92 μg/mL). Meanwhile, microscale thermophoresis (MST) indicated that compound 4l have strong binding capability to tobacco mosaic virus coat protein (TMV-CP) with dissociation constant (Kd) values of 0.34 μmol/L, which was better than ningnamycin (0.52 μmol/L). These results suggest that novel myricetin derivatives bearing ferulic acid amide scaffolds may be considered as an activator for antiviral agents.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
24 November 2019
Commenter:
Wei Xue
Commenter's Conflict of Interests:
Author
Comment:
Since "Scheme 1. Synthesis of the title compounds 4a–4v” shows that the Chemdraw format is garbled after being converted to PDF, the picture is converted to jpg format and re-uploaded. Scheme 1. Synthesis of the title compounds 4a–4v.
Commenter: Wei Xue
Commenter's Conflict of Interests: Author